Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-11-14
2011-12-06
Ton, Thaian N (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S093100
Reexamination Certificate
active
08071740
ABSTRACT:
Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
REFERENCES:
patent: 4866042 (1989-09-01), Neuwelt
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5635385 (1997-06-01), Leopold et al.
patent: 5686281 (1997-11-01), Roberts
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5747340 (1998-05-01), Harats et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5882893 (1999-03-01), Gardener et al.
patent: 5906827 (1999-05-01), Khouri et al.
patent: 5916763 (1999-06-01), Williams et al.
patent: 6027743 (2000-02-01), Khouri et al.
patent: 6110480 (2000-08-01), Chu et al.
patent: 6180355 (2001-01-01), Alexander et al.
patent: 6183737 (2001-02-01), Zaleske et al.
patent: 6200751 (2001-03-01), Gu et al.
patent: 6206917 (2001-03-01), Williams et al.
patent: 6239151 (2001-05-01), Broadhurst et al.
patent: 6265216 (2001-07-01), Bennett et al.
patent: 6300127 (2001-10-01), Hair et al.
patent: 6300490 (2001-10-01), Huber et al.
patent: 6348209 (2002-02-01), Placke et al.
patent: 6376244 (2002-04-01), Atala
patent: 6438802 (2002-08-01), Beeman et al.
patent: 6444803 (2002-09-01), Hair et al.
patent: 6479064 (2002-11-01), Atala
patent: 6497725 (2002-12-01), Williams et al.
patent: 6503886 (2003-01-01), Baird et al.
patent: 6521750 (2003-02-01), Hair et al.
patent: 6545048 (2003-04-01), Patterson et al.
patent: 6576265 (2003-06-01), Spievack
patent: 6579697 (2003-06-01), Wallach et al.
patent: 6627189 (2003-09-01), Roth et al.
patent: 6652583 (2003-11-01), Hopkins et al.
patent: 6783776 (2004-08-01), Spievack
patent: 6866864 (2005-03-01), Mousa
patent: 7067649 (2006-06-01), Harats
patent: 7585666 (2009-09-01), Harats et al.
patent: 7625558 (2009-12-01), Greene et al.
patent: 2003/0124100 (2003-07-01), Harats
patent: 2004/0048280 (2004-03-01), Harats
patent: 2004/0197860 (2004-10-01), Harats et al.
patent: 2004/0224389 (2004-11-01), Bellgrau et al.
patent: 2005/0112110 (2005-05-01), Harats
patent: 2005/0186179 (2005-08-01), Harats et al.
patent: 2006/0204478 (2006-09-01), Harats et al.
patent: 2007/0286845 (2007-12-01), Harats et al.
patent: 2008/0305088 (2008-12-01), Harats et al.
patent: 2009/0326052 (2009-12-01), Harats et al.
patent: 2010/0282634 (2010-11-01), Harats et al.
patent: 19838837 (2000-03-01), None
patent: WO 98/00013 (1998-01-01), None
patent: WO 98/37901 (1998-03-01), None
patent: WO 98/00013 (1998-08-01), None
patent: WO 98/37901 (1998-09-01), None
patent: WO 00/06759 (2000-02-01), None
patent: WO 02/40629 (2002-05-01), None
patent: WO 03/033514 (2003-04-01), None
patent: WO 03/093409 (2003-11-01), None
patent: WO 2004/113497 (2004-12-01), None
patent: WO 2006/051545 (2006-05-01), None
patent: WO 2007/096882 (2007-08-01), None
patent: WO 2008/132729 (2008-11-01), None
Koshikawa et al (2000, Cancer Research, vol. 60, pp. 2936-2941).
Communication Pursuant to Article 94(3) EPC Dated May 29, 2008 From the European Patent Office Re.: Application No. 05806361.1 Mailed by Associate on Jun. 16, 2008.
Communication Pursuant to Article 96(2) EPC Dated Apr. 17, 2007 From the European Patent Office Re.: Application No. EP 02801473.6.
Examination Report Dated Sep. 5, 2005 from the Intellectual Property Office of New Zealand Re.: Application 536578 Mailed by Associate Oct. 12, 2005.
International Preliminary Examination Report Dated May 26, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL03/00347.
Official Action Dated Nov. 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated May 28, 2008 From the Japanese Patent Office Re.: Application No. 202-543626 Mailed by Associate Jun. 9, 2008.
Communication Pursuant to Article 94(3) EPC Dated Feb. 10, 2009 From the European Patent Office Re.: Application No. 02801473.6.
Communication Pursuant to Article 94(3) EPC Dated Feb. 16, 2009 From the European Patent Office Re.: Application No. 05806361.1.
Examiner's Report Dated Dec. 10, 2008 From the Australian Government, IP Australia Re.: Application No. 2003222427.
Requisition by the Examiner Dated Dec. 16, 2008 From the Canadian Intellectual Property Re.: 2,429,342.
Translation of Notice of the Reason for Rejection Dated Jan. 7, 2009 From the Korean Intellectual Property Office Re.: Application No. 2008-7018598.
Communication Pursuant to Article 94(3) EPC Dated Apr. 27, 2007 From the European Patent Office Re.: Application No. 01996590.4.
Communication Pursuant to Article 96(2) EPC Dated Dec. 21, 2006 From the European Patent Office Re.: Application No. 01996590.4.
Examination Report Dated Apr. 3, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 555612.
International Preliminary Examination Report Dated Jan. 5, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL02/00339.
International Preliminary Report on Patentability Dated Jan. 22, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2007/000242.
International Preliminary Report on Patentability Dated May 24, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/001195.
International Search Report Dated Apr. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL08/00543.
Invitation to Pay Additional Fees Dated Jun. 1, 2006 From the International Searching Authority Re.: Application No. PCT/IL05/01195.
Notice of Allowance Dated Aug. 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/075,619.
Office Action Dated Jan. 10, 2008 From the Israeli Patent Office Re.: Application No. 155940.
Office Action Dated Sep. 20, 2007, From the Israeli Patent Office Re.: Application No. 155940.
Official Action Dated Jun. 4, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/975,619.
Official Action Dated May 6, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Apr. 9, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/940,746.
Official Action Dated Jul. 10, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Nov. 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Dec. 29, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Supplementary European Search Report Dated Mar. 21, 2006 From the European Patent Office Re.: Application No. 02801473.6.
Written Opinion Dated Apr. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL08/00543.
Examination Report Dated Aug. 6, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 555612.
Official Action Dated Jun. 24, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Jul. 13, 2009 From the European Patent Office Re.: Application No. 05806361.1.
Folkman “Angiogenesis and Apoptosis”, Seminars in Cancer Biology, 13: 159-167, 2003.
Juengst “What Next for Human Gene Therapy? Fene Transfer Often Has Multiple and Unpredictable Effects on Cells”, BMJ, 326: 1410-1411, Jun. 28, 2003.
Kay et al. “Viral Vectors for Gene Therapy: The Art of Turning Infectious Agents Into Vehicles of Therapeutics”, Nature Medicine, 7(1): 33-40, Jan. 2001.
Lebedeva et al. “Restoring Apoptosis as A Strategy for Cancer Gene Therapy: Focus on P53 and MDA-7”, Seminars in Cancer Biology, 13: 169-178, 2003.
Patil et al. “DNA-Based Therapeutics and DNA Delivery Systems: A Comprehensive Review”, The AAPS Journal, 7(1): E61-E77, 2005.
Savontaus et al. “Transcriptional Targeting of Conditionally Replicating Adenovirus to Dividing Endothelial Cells”, Gene Therapy, 9: 972-979, 2002.
Aird et al. “Human von Willebrand Factor Gene Sequences Target
Bangio Livnat
Breitbart Eyal
Greenberger Shoshana
Harats Dror
Peled Michael
Noble Marcia S
Ton Thaian N
Vascular Biogenics Ltd.
LandOfFree
Promoters exhibiting endothelial cell specificity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Promoters exhibiting endothelial cell specificity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Promoters exhibiting endothelial cell specificity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307780